Prelude Therapeutics is a clinical-stage precision oncology company developing small-molecule medicines aimed at high-unmet-need cancers. Its programs focus on novel targets and mechanisms intended to treat molecularly defined patient populations rather than broad, non-selective chemotherapies. Based in Wilmington, Delaware, the company generates limited revenue while advancing candidates through clinical development.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q1 2025 | 0 | — | -32.1 | — |
| Q2 2025 | 0 | — | -31.2 | — |
| Q3 2025 | 6.5 | — | -19.7 | — |
| Q4 2025 | 5.6 | — | -16.5 | — |
| Q1 2026 | 4.6 | — | -10.4 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Infinite Eagle Acquisition Corp. (IEAG), Carlsmed, Inc. (CARL), Algoma Steel Group Inc. (ASTL), Innovative Aerosystems, Inc. (ISSC), Q32 Bio Inc. (QTTB), 908 Devices Inc. (MASS)